Poor outcomes in patients with lung cancer who take KRAS G12C inhibitors are linked to mutations in three important genes.

Published Date: 19 Apr 2023

Three tumor suppressor genes—KEAP1, SMARCA4, and CDKN2A—have co-occurring mutations, and these mutations have been linked to poor clinical outcomes, according to a recent study led by scientists at The University of Texas MD Anderson Cancer Center.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Americans Are Surviving Cancer. But the Mental Health Challenges Can Persist.

2.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

3.

We Don't Always Know What's 'Best' for Our Patients

4.

Should the UK introduce targeted prostate cancer screening? The case for and against

5.

Germline Profiling May Improve Risk Stratification in t-MNs


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot